Dr. Victoria Demby

Victoria Elizabeth Demby, Ph.D. is a seasoned global regulatory affairs leader with over 25 years of experience spanning oncology, cell and gene therapy, immunology, neurology, cardio-renal, and metabolic diseases. She has held senior executive roles and roles of increasing responsibilities at Adlai Nortye, GlaxoSmithKline, Merck, and Bristol-Myers Squibb, and currently serves as Senior Vice President of Global Regulatory Affairs and Quality at Third Arc Bio, while also leading her own regulatory consultancy. Dr. Demby has successfully driven global regulatory strategies leading to global approvals of blockbuster therapies including Keytruda, Eliquis, Januvia, and Orencia. A mentor and professor, she is frequently invited to speak on regulatory science and serves as Adjunct Assistant Professor at George Washington University. She earned her Ph.D. in Pharmacology and Toxicology from the University of Kansas and her B.S. in Biochemistry from the University of Vermont.